{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:17:30Z","timestamp":1793812650866,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research fund from Mutual Aid Medical Society","award":["469"],"award-info":[{"award-number":["469"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF). While AFF has been reported in patients with osteoporosis receiving denosumab, data are scarce in the context of AFF occurring in patients with bone metastasis receiving monthly denosumab therapy.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To analyze the incidence of AFF in patients with bone metastasis, we reviewed the medical records of patients who had received monthly denosumab (120\u2009mg) treatment from May 2012 to June 2017 at any of the three participant institutions.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study population consisted of 277 patients who had received a median of 10 doses (range, 1\u201379) of denosumab. Five patients were diagnosed as having AFF or symptomatic atypical femoral stress reaction (AFSR) needing surgical intervention, representing an incidence rate of 1.8% (95% confidence interval, 0.77\u20134.2). These patients had received 15, 45, 45, 46 or 47 doses of denosumab, respectively. Four of the patients had received prior zoledronic acid treatment. The results of our analysis suggested that long-term use of denosumab, especially for more than 3.5\u2009years, and prior use of zoledronic acid were risk factors for the development of AFF.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We found the AFF events in 5 patients (1.8%) among 277 cancer patients who had received monthly denosumab (120\u2009mg) treatment. Long-term denosumab treatment and prior zoledronic acid treatment were identified as risk factors for the development of AFF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6236-6","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:29:57Z","timestamp":1571804997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"Momoko","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8064-648X","authenticated-orcid":false,"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kinowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Umezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shigekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"15","key":"6236_CR1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314\u201321. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.05.116\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"5","key":"6236_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082\u201390.","journal-title":"Cancer."},{"issue":"1","key":"6236_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36\u201343. \n                    https:\/\/doi.org\/10.1002\/cncr.11892\n                    \n                  .","journal-title":"Cancer"},{"issue":"11","key":"6236_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879\u201382.","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"6236_CR5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6\n                    \n                  .","journal-title":"Lancet"},{"issue":"3","key":"6236_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679\u201387. \n                    https:\/\/doi.org\/10.1007\/s00520-013-2022-1\n                    \n                  .","journal-title":"Support Care Cancer"},{"issue":"9","key":"6236_CR7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125\u201332. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.31.3304\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"16","key":"6236_CR8","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"17","key":"6236_CR9","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","volume":"18","author":"M Martin","year":"2012","unstructured":"Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18(17):4841\u20139. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3310\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"12","key":"6236_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823\u20139. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e31826aec2b\n                    \n                  .","journal-title":"J Thorac Oncol"},{"issue":"35","key":"6236_CR11","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.29.7101\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"3","key":"6236_CR12","first-page":"1245","volume":"34","author":"K Hayashi","year":"2014","unstructured":"Hayashi K, Aono M, Shintani K, Kazuki K. Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review. Anticancer Res. 2014;34(3):1245\u20139.","journal-title":"Anticancer Res"},{"issue":"13","key":"6236_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2106\/JBJS.J.01199","volume":"93","author":"ME Puhaindran","year":"2011","unstructured":"Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am. 2011;93(13):1235\u201342. \n                    https:\/\/doi.org\/10.2106\/JBJS.J.01199\n                    \n                  .","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"6236_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1\u201323. \n                    https:\/\/doi.org\/10.1002\/jbmr.1998\n                    \n                  .","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6236_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","volume":"16","author":"J Starr","year":"2018","unstructured":"Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and Management of Atypical Femur Fractures. Curr Osteoporos Rep. 2018;16(4):519\u201329. \n                    https:\/\/doi.org\/10.1007\/s11914-018-0464-6\n                    \n                  .","journal-title":"Curr Osteoporos Rep"},{"issue":"11","key":"6236_CR16","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483\u201392. \n                    https:\/\/doi.org\/10.1210\/jc.2013-1597\n                    \n                  .","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6236_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/17453674.2013.854668","volume":"85","author":"E Drampalos","year":"2014","unstructured":"Drampalos E, Skarpas G, Barbounakis N, Michos I. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 2014;85(1):3\u20135. \n                    https:\/\/doi.org\/10.3109\/17453674.2013.854668\n                    \n                  .","journal-title":"Acta Orthop"},{"issue":"3","key":"6236_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00774-014-0606-6","volume":"33","author":"KS Khow","year":"2015","unstructured":"Khow KS, Yong TY. Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab. 2015;33(3):355\u20138. \n                    https:\/\/doi.org\/10.1007\/s00774-014-0606-6\n                    \n                  .","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"6236_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/17453674.2014.885355","volume":"85","author":"J Schilcher","year":"2014","unstructured":"Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab--a case report. Acta Orthop. 2014;85(1):6\u20137. \n                    https:\/\/doi.org\/10.3109\/17453674.2014.885355\n                    \n                  .","journal-title":"Acta Orthop"},{"key":"6236_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bone.2013.12.027","volume":"61","author":"RN Thompson","year":"2014","unstructured":"Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. Bone. 2014;61:44\u20137. \n                    https:\/\/doi.org\/10.1016\/j.bone.2013.12.027\n                    \n                  .","journal-title":"Bone."},{"key":"6236_CR21","doi-asserted-by":"publisher","first-page":"249872","DOI":"10.1155\/2013\/249872","volume":"2013","author":"J Villiers","year":"2013","unstructured":"Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol. 2013;2013:249872. \n                    https:\/\/doi.org\/10.1155\/2013\/249872\n                    \n                  .","journal-title":"Case Rep Rheumatol"},{"issue":"4","key":"6236_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1634\/theoncologist.2016-0192","volume":"22","author":"SP Yang","year":"2017","unstructured":"Yang SP, Kim TW, Boland PJ, Farooki A. Retrospective review of atypical femoral fracture in metastatic Bone disease patients receiving Denosumab therapy. Oncologist. 2017;22(4):438\u201344. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2016-0192\n                    \n                  .","journal-title":"Oncologist"},{"issue":"3","key":"6236_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/17453674.2016.1277412","volume":"88","author":"DC Austin","year":"2017","unstructured":"Austin DC, Torchia MT, Klare CM, Cantu RV. Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. Acta Orthop. 2017;88(3):351\u20133. \n                    https:\/\/doi.org\/10.1080\/17453674.2016.1277412\n                    \n                  .","journal-title":"Acta Orthop"},{"issue":"6","key":"6236_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/RLU.0000000000001592","volume":"42","author":"M Koizumi","year":"2017","unstructured":"Koizumi M, Gokita T, Toda K. Impending atypical femoral fracture in patients with medullary thyroid Cancer with skeletal metastasis treated with long-term bisphosphonate and Denosumab. Clin Nucl Med. 2017;42(6):463\u20134. \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000001592\n                    \n                  .","journal-title":"Clin Nucl Med"},{"issue":"4","key":"6236_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12282-016-0746-8","volume":"24","author":"S Ota","year":"2017","unstructured":"Ota S, Inoue R, Shiozaki T, Yamamoto Y, Hashimoto N, Takeda O, et al. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. Breast Cancer. 2017;24(4):601\u20137. \n                    https:\/\/doi.org\/10.1007\/s12282-016-0746-8\n                    \n                  .","journal-title":"Breast Cancer"},{"issue":"5","key":"6236_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/RLU.0000000000002058","volume":"43","author":"T Sugihara","year":"2018","unstructured":"Sugihara T, Koizumi M, Hayakawa K, Ito Y, Sata N. Impending atypical femoral fracture in a patient of breast Cancer with Bone metastases receiving long-term Denosumab. Clin Nucl Med. 2018;43(5):365\u20136. \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000002058\n                    \n                  .","journal-title":"Clin Nucl Med"},{"issue":"3","key":"6236_CR27","doi-asserted-by":"publisher","first-page":"230949901772791","DOI":"10.1177\/2309499017727916","volume":"25","author":"D Tateiwa","year":"2017","unstructured":"Tateiwa D, Outani H, Iwasa S, Imura Y, Tanaka T, Oshima K, et al. Atypical femoral fracture associated with bone-modifying agent for bone metastasis of breast cancer: A report of two cases. J Orthop Surg (Hong Kong). 2017;25(3):2309499017727916. \n                    https:\/\/doi.org\/10.1177\/2309499017727916\n                    \n                  .","journal-title":"J Orthop Surg (Hong Kong)"},{"issue":"3","key":"6236_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","volume":"99-B","author":"A Koh","year":"2017","unstructured":"Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J. 2017;99-B(3):295\u2013302. \n                    https:\/\/doi.org\/10.1302\/0301-620X.99B3.BJJ-2016-0276.R2\n                    \n                  .","journal-title":"Bone Joint J"},{"issue":"3","key":"6236_CR29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294\u2013301. \n                    https:\/\/doi.org\/10.1210\/jc.2004-0952\n                    \n                  .","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6236-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:06:02Z","timestamp":1603235162000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6236"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6236-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"12 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Opt-out consent was obtained instead of informed consent according to Institutional Review Board of Toranomon Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Toshimi Takano has competing interest with Daiichi-Sankyo, Kyowa Hakko Kirin, and Eisai. Other members have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"980"}}